01—Abstract
Summary
Summary of the 10-Q filed October 31, 2025. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation reported a solid third quarter for fiscal year 2025, with net sales increasing by 10.3% year-over-year to $6.06 billiona.
This growth was driven by a robust 9.6%b increase in constant currency, with nearly all segments contributing to higher unit volumes. The MedSurg and Neurotechnology segment showed particularly strong performance, with a 14.4% reported sales increase, bolstered by the recent acquisition of Inari Medical. The Orthopaedics segment also saw positive growth, albeit at a more moderate pace of 3.9%.
Net earnings for the quarter were $859 millionc, a slight increase from $834 million in the prior year, resulting in diluted earnings per share of $2.22, up from $2.16. While overall operating income saw a marginal increase, the operating income margin slightly compressed due to various factors including integration costs from the Inari acquisition and increased selling, general, and administrative expenses. Despite these pressures, the company maintains a strong financial position with healthy cash flow from operations.
02—Key points
Key Highlights
- Net sales grew 10.3% year-over-year to $6.06 billion, with 9.6% growth in constant currency, indicating strong underlying demand across segments.
- MedSurg and Neurotechnology segment sales increased by 14.4%, significantly boosted by the acquisition of Inari Medical.
- Diluted EPS rose to $2.22 from $2.16 in the prior year's third quarter, demonstrating improved profitability on a per-share basis.
- Operating income saw a modest increase, but the operating margin compressed slightly, reflecting investment in growth and acquisition integration.
- The company generated strong cash flow from operations, totaling $2.9 billion for the nine months ended September 30, 2025, supporting financial flexibility.
- Stryker continued to manage its debt effectively, issuing new notes and maintaining compliance with credit facility covenants.
- Goodwill and other impairments increased significantly compared to the prior year, primarily related to the sale of the Spinal Implants business.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Stryker Corp kept $0.14.
- Revenue$6.06B100.0%
- Cost of revenue−$2.21B36.4%
- Gross profit$3.85B63.6%
- Operating costs−$2.72B44.9%
- Operating income$1.14B18.7%
- Interest, other & tax−$276.0M4.6%
- Net income$859.0M14.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 31, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $6.06B$5.49B | +10.2% |
| Cost of Revenue | $2.21B$1.98B | +11.5% |
| Gross Profit | $3.85B$3.52B | +9.5% |
| R&D Expenses | $410.00M$377.00M | +8.8% |
| SG&A Expenses | $2.04B$1.89B | +8.0% |
| Operating Expenses | $2.72B$2.43B | +11.7% |
| Operating Income | $1.14B$1.08B | +4.6% |
| Interest Expense | $157.00M$98.00M | +60.2% |
| Net Income | $859.00M$834.00M | +3.0% |
| EPS (Basic) | $2.25$2.18 | +3.2% |
| EPS (Diluted) | $2.22$2.16 | +2.8% |
| Shares Outstanding (Basic) | 382.40M381.10M | +0.3% |
| Shares Outstanding (Diluted) | 386.70M385.60M | +0.3% |
05—Questions
Frequently Asked Questions
What drove the significant increase in MedSurg and Neurotechnology segment sales?
The MedSurg and Neurotechnology segment's strong performance, with a 14.4% increase in net sales, was largely driven by organic growth across its various businesses and the impactful acquisition of Inari Medical completed in the first quarter of 2025.
How did the Inari Medical acquisition impact Stryker's financials?
The acquisition of Inari Medical for approximately $4.81 billion significantly contributed to the growth in the MedSurg and Neurotechnology segment and the overall company's net sales. It also led to increased selling, general, and administrative expenses and goodwill, reflecting the strategic benefits and integration costs associated with the deal.
What is the outlook for gross profit margin given the segment sales mix?
While gross profit margin remained relatively stable year-over-year for the quarter, the company anticipates a potential unfavorable impact on gross profit margin in the future due to a faster sales growth rate in the lower gross margin MedSurg and Neurotechnology segment compared to the Orthopaedics segment.
How is Stryker managing its debt and liquidity?
Stryker demonstrated strong liquidity, with cash from operations of $2.9 billion for the nine months. The company also issued new senior unsecured notes and entered into a new revolving credit agreement, increasing its borrowing capacity. They are compliant with all debt covenants and believe they have sufficient resources to meet their liquidity needs.
06—Continue